Felzartamab is a CD38-targeting human monoclonal antibody, with Felzartamab approved for multiple myeloma in China and under clinical development for IgA nephropathy, primary membranous nephropathy, and kidney transplant antibody-mediated rejection. Recently, information published on the official website of the NMPA…
Tinengotinib approved for cholangiocarcinoma marks an important advance for patients with FGFR2 fusion or rearrangement-positive disease who have progressed after FGFR inhibitor therapy. As a China-developed multi-target kinase inhibitor, it is the first globally approved treatment specifically for this patient…
The breast cancer drug list in China mainly includes endocrine therapy drugs, HER2-targeted drugs, CDK4/6 inhibitors, mTOR inhibitors, PARP inhibitors, antibody-drug conjugates (ADCs), chemotherapy drugs, and immunotherapy drugs. Breast cancer is one of the most common malignant tumors. Treatment options…
Key Takeaways Melanoma is a malignant tumor that originates from melanocytes and most commonly develops in the skin. So, how to identify the early signs of melanoma? What changes in an ordinary mole should raise concern? This article is prepared…
What are the most common chemotherapy drugs? Common chemotherapy drugs include Cisplatin, Carboplatin, Oxaliplatin, Paclitaxel, Docetaxel, Gemcitabine, Pemetrexed, Fluorouracil (5-FU), Capecitabine, and Irinotecan. Chemotherapy is one of the most important treatment options for cancer. It uses medications to destroy or…
Recibokibart approved for GPP marks a major milestone in Generalized Pustular Psoriasis (GPP) treatment. Developed by Shanghai Huaota Biopharmaceutical Co., Ltd., this IL-36R monoclonal antibody was approved by the NMPA on July 29, 2026, for adult patients with acute GPP…
Common drugs for prostate cancer include androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), PARP inhibitors, chemotherapy, PSMA-targeted radioligand therapy, immunotherapy, and bone-targeted therapies. Prostate cancer is one of the most common cancers affecting men worldwide and remains a…
Plozasiran now available in China marks a milestone for FCS patients, offering a new APOC3-targeted siRNA therapy to help lower triglyceride (TG) levels in adults with familial chylomicronemia syndrome. In July 2026, Sanofi announced that Plozasiran Sodium Injection (brand name:…
Ciprocopan approved in China as the world’s first once-daily oral Complement Factor B (CFB) inhibitor, bringing a new oral treatment option for patients with paroxysmal nocturnal hemoglobinuria (PNH). On July 23, 2026, China’s National Medical Products Administration (NMPA) approved Haisco’s…
Oveporexton approved first in China, becoming the world’s first approved selective orexin receptor 2 (OX2R) agonist and the first therapy designed to target the underlying mechanism of Type 1 narcolepsy (NT1). On July 21, 2026, the NMPA approved Oveporexton for…
